Cessation of Prior Bispecific Antibody Therapy in ZUMA-1 and ZUMA-7

ZUMA-5 Study

ZUMA-7

Cessation of Prior Therapies in ZUMA-1 and ZUMA-7

Use in HBV infection

Long-term Follow-up from ZUMA-1

Outpatient Use

Persistence and expansion of CAR T Cells

Retreatment Data from ZUMA-1

ZUMA-1 Cohort 6

Outcomes by Age

Outcomes in Elderly Patients in ZUMA-7

Cessation of Prior Therapies in ZUMA-5

Post-Infusion Monitoring

Use of tocilizumab biosimilars for REMS Program

Use in HCV infection

Use in Patient with HIV

Alternative Therapies to tocilizumab

CD19 Expression and Outcomes

CNS Lymphoma

Retreatment in ZUMA-3

Use of tocilizumab biosimilars for REMS

Use in Burkitts Lymphoma

Primary Analysis of ZUMA-2 Cohort 3

Cessation of Prior Therapies ZUMA-3

Efficacy Outcomes with or without Subsequent AlloSCT

Incidence of GvHD in ZUMA-3

MRD Outcomes in ZUMA-3

Long-term Follow-up of the ZUMA-2 Study

Retreatment in ZUMA-2

Alternative Therapies to Tocilizumab

Long-term follow up of the ZUMA-3 Study

Bendamustine Use Prior to Enrollment in ZUMA-2

Cessation of Prior Therapies for MCL ZUMA-2

The prognostic value of POD24 in relapsed/refractory follicular lymphoma – A SCHOLAR-5 analysis

‘Don’t keep me waiting’: estimating the impact on lifetime survival and QALYs of reduced vein-to-vein time for LBCL patients treated with CAR T in the 3L+ setting

The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma – a Large, Multicenter Study

Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 38.1-Month Median Follow-up

Estimating the survival impact of not receiving CAR T therapy while being eligible for treatment

The cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy in patients with large B-cell lymphoma in Sweden

Single cell analysis reveals immune dysfunction in Large B cell Lymphoma (LBCL) pts with hypomagnesemia receiving Axi-cel: results from ZUMA-1 trial and Mayo Clinic cohort

Matching-Adjusted Indirect Comparisons of Axi-cel to Mosunetuzumab for the Treatment of Relapsed/Refractory Follicular Lymphoma

Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA-7 Study of Axicabtagene Ciloleucel Versus Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma

Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial

Real-World Treatment Patterns of Large B-Cell Lymphoma Patients Over Time in a Post-CAR T Approval Era

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma in the US: A CIBMTR Report

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Mantle Cell Lymphoma Who Are Naive to Bruton Tyrosine Kinase Inhibitors

Axicabtagene Ciloleucel Vein-to-vein Time in Trial or Real-world Settings vs Other CAR T-cell Therapies for Relapsed/Refractory Large B-cell Lymphoma: a Systematic Literature Review and Meta-analysis

Cost-Effectiveness of Axicabtagene Ciloleucel Vs. Tisagenlecleucel for the Treatment of 3L+ Relapsed/Refractory Large B-Cell Lymphoma in the United States: Incorporating Longer Survival Results

Updated Trends in Real-World Outpatient Administration of Axicabtagene Ciloleucel and Brexucabtagene Autoleucel in Relapsed/Refractory Non-Hodgkin Lymphoma

Phase 1 Study Of CART-ddBCMA For The Treatment Of Patients With Relapsed And/Or Refractory Multiple Myeloma: Results From At Least 1-year Follow-up In All Patients

Treatment Preferences and Quality of Life in Patients with Relapsed / Refractory Follicular Lymphoma

Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada

ZUMA-24 Preliminary Analysis: A Phase 2 Study of Axicabtagene Ciloleucel in the Outpatient Setting With Prophylactic Corticosteroids in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Cost-effectiveness and Budget Impact Analyses of Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma in Singapore

Real-World Safety Outcomes of Axicabtagene Ciloleucel in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Europe and United States: A Systematic Review and Meta-Analysis

Real-World Manufacturing Experience of Axicabtagene Ciloleucel for Patients Treated in Second Line Versus Third Line of Therapy and Beyond

Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (axi-cel) and Glofitamab (glofit) in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) After at Least Two Prior Systemic Therapies (3L+)

Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (axi-cel) and Epcoritamab (epcor) in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) After at Least Two Prior Systemic Therapies (3L+)

Feasibility and Safety of Outpatient Administration of Chimeric Antigen Receptor T-cell Therapy: A Systematic Literature Review of Early U.S. Experience

Optimizing Care After CAR T-cell Therapy: Reduction of Daily Monitoring Duration Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Infusion

CARe-Together: the first italian Patient Support Program for CAR T patients

Manufacturing Commercial Axicabtagene Ciloleucel (Axi-Cel) in Italy for patients with relapsed/refractory NHL: A 2-Year Retrospective Analysis

Increasing CAR T delivery capacity in certified healthcare facilities: An impact assessment of shifting resources from ASCT to CAR T in second-line treatment of diffuse large B-cell lymphoma

ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel VersusStandard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma

Access to CAR T-Cell Therapy in the US and its Potential Impact on Health Inequities

Axicabtagene Ciloleucel Manufacturing Experience From Launch to Present Day: a United States Perspective

Real time, point-of-need measurement of Blood CD19 CAR-T vector load is concordant with standard ddPCR method

Impact of Complete Response on Long-Term Survival Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma

Minority Patients Receiving CAR T-Cell Therapy in the United States Between 2020-2025: A SEER-Based Projection on Racial Composition and Impact of Proximity to Authorized Treatment Centers

An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

A cost-effectiveness analysis of axicabtagene ciloleucel versus epcoritamab in third-line diffuse large B-cell lymphoma patients in the United States

A cost-effectiveness analysis of axicabtagene ciloleucel versus glofitamab in third-line diffuse large B-cell lymphoma patients in the United States

Contemporary Treatment Options Beyond Chimeric Antigen Receptor T-Cell Therapies for Patients With Relapsed or Refractory Large B-Cell Lymphoma: A Systematic Literature Review

Medicare Utilization and Cost Trends for CAR T Cell Therapies in the Treatment of Large B-Cell Lymphoma

Rapid Increase in Blood CD19 CAR-T Vector Load during the First five Days Post Infusion Is Associated with Severe ICANS

Incidence of Cytokine Release Syndrome and Neurological Events in Patients With Relapsed or Refractory Large B-Cell Lymphoma at and Beyond 2 Weeks Following Axicabtagene Ciloleucel Infusion

A United States (US) Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Compared to Odronextamab in Third Line or Later (3L+) Diffuse Large B-Cell Lymphoma

Time to CAR T infusion in local versus distant treatment centers

In vitro and in vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, including a Dysfunctional CD8+ T Cell State Characterized by the GATA3 overexpression

Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care (SOC) in Patients With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)

ZUMA-22: A Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients With Relapsed or Refractory Follicular Lymphoma

Real-World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory Mantle Cell Lymphoma: A CIBMTR Subgroup Analysis by Prior Treatment

Circulating Tumor DNA by ClonoSEQ to Monitor Residual Disease After Axicabtagene Ciloleucel in Large B-cell Lymphoma

Impact of Age, Prior Therapies, and Subsequent Transplant on Long-term Outcomes of Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Treated With Brexucabtagene Autoleucel in ZUMA-3

ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard of Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma

Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA-7 Study of Axicabtagene Ciloleucel Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma

A Pilot Study of Axicabtagene Ciloleucel in Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas (PCNSL & SCNSL)

Long-Term Survival Outcomes of Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Brexucabtagene Autoleucel in ZUMA-3

A Retrospective Intrapatient Analysis From ZUMA-5: Axicabtagene Ciloleucel (Axi-Cel) Compared With Prior Standard-of-Care Therapy in Patients With Relapsed/Refractory Follicular Lymphoma

Real-World Outcomes of Brexucabtagene Autoleucel for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia: Evidence From The CIBMTR Registry

Real World Data of Axicabtagene Ciloleucel as Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a LYSA Study from the French DESCAR-T Registry

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel as First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma

Matching-adjusted indirect comparison (MAIC) of brexucabtagene autoleucel (brexu-cel) and pirtobrutinib in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) previously treated with a covalent bruton tyrosine kinase inhibitor (cBTKI)

Real-World Evidence in the United States on the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Phase 1 Study Of CART-ddBCMA For The Treatment Of Patients With Relapsed And/Or Refractory Multiple Myeloma: Results From At Least 1-year Follow-up In All Patients

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel in ZUMA-2 and ZUMA-18, an Expanded Access Study

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment

An Updated Comparison of Clinical Outcomes From 4-Year Follow-Up of ZUMA-5 (Axicabtagene Ciloleucel) and the International SCHOLAR-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma

Comparative Effectiveness of Axicabtagene Ciloleucel Versus Historical Standard of Care in Patients With Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Real-World Outcomes of Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma: A CIBMTR Subgroup Analysis of High-Risk Characteristics

Improved Overall Survival With Axicabtagene Ciloleucel vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Pre- and post-treatment immune contexture correlates with long term response in large B cell lymphoma patients treated with Axicabtagene ciloleucel (axi-cel)

Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): an Exploratory Long-Term Survival Assessment in Patients With Refractory Large B-Cell Lymphoma From ZUMA-1

Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-Up From the Phase 2 ZUMA-5 Trial

Cost-Effectiveness of Axicabtagene Ciloleucel Versus Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma in the US

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events After Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory Mantle Cell Lymphoma in ZUMA-2

Economic Burden Associated with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nationwide Health Insurance Claims Database Study in Japan During 2012-2022

Impact of Disease Burden, CAR-T Expansion, and Mononuclear Cell Recovery on Overall Response and Duration of Response in ZUMA-3 Pivotal Study

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results From the iMMagine-1 Trial

Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients With Relapsed/Refractory Large B-Cell Lymphoma

Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients With Relapsed/Refractory Large B-Cell Lymphoma

KITE-753: An Autologous Rapid Manufactured Anti-CD19/CD20 CAR-T Product for the Treatment of B-cell Malignancies

5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel

Predictors of Early Safety Outcomes With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Five-Year Outcomes of Patients With Relapsed or Refractory Mantle Cell Lymphoma Treated With Brexucabtagene Autoleucel in ZUMA-2 Cohorts 1 and 2

Real-World Outcomes for Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia by High-Risk Features and Prior Treatments: Updated Evidence From the CIBMTR Registry

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma

Earlier Corticosteroid Use for Adverse Event Management in Patients Receiving Axicabtagene Ciloleucel for Large B-Cell Lymphoma

Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma

Prophylactic Corticosteroid Use in Patients Receiving Axicabtagene Ciloleucel for Large B-Cell Lymphoma

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Outcomes of Axicabtagene Ciloleucel Versus Standard of Care in Patients 65 Years of Age or Older With Relapsed/Refractory Large B-Cell Lymphoma

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma